John B. Buse, MD, PhD

Chief, Division of Endocrinology
Verne S. Caviness Distinguished Professor
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute

Specialty Areas: Prevention and treatment of type 1 diabetes, type 2 diabetes and their complications.

Chronology: MD: Duke University, 1986; PhD: Duke University, 1986; Intern and Resident: University of Chicago, 1986-1988; Endocrinology, Diabetes and Metabolism Fellowship: University of Chicago, 1988-1991; Chief Resident and Instructor: University of Chicago, 1990; Assistant Professor of Medicine: University of Chicago, 1992-1994; Associate Professor of Medicine: University of North Carolina, 1994-2006; Chief: Division of General Medicine and Clinical Epidemiology, University of North Carolina, 2001-2006; Professor of Medicine: University of North Carolina, 2006-present; Chief: Division of Endocrinology, University of North Carolina, 2006-present; Director: Diabetes Center for Excellence, University of North Carolina, 2010-present; Executive Associate Dean for Clinical Research: University of North Carolina, 2011-present; Director: NC Translational and Clinical Sciences Institute, University of North Carolina, 2015-present.

Note: Not accepting new patients at this time.

Dr. Buse’s practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications. He practices patient-centered care focusing on developing treatment programs in collaboration with patients that meet their needs and expectations. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care.

Dr. Buse works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care. Dr. Buse also plays a significant role in research administration, having been Executive Associate Dean for Clinical Research since 2011 and Director of the NC Translational and Clinical Sciences Institute since 2015.

Selected Bibliography:

Chen Z, Wang J, Sun W, Archibong E, Kahkoska AR, Zhang X, Lu Y, Ligler FS, Buse JB, Gu Z. Synthetic beta cells for fusion-mediated dynamic insulin secretion. Nat Chem Biol. 2018; 14:86-93. PMID: 29083418.

Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med 2017; 377:2337-2348. PMID:28899222

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017; 377:723-732. PMID: 28605603.

Young LA, Buse JB, Weaver MA, Vu MB, Mitchell CM, Blakeney T, Grimm K, Rees J, Niblock F, Donahue KE; Monitor Trial Group. Glucose Self-monitoring in Non-Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. JAMA Intern Med. 2017; 177:920-929. PMID: 28600913.

El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, Mondesir D, Esmaeili A, Hartigan C, Thompson MJ, Malkani S, Lock JP, Harlan DM, Clinton P, Frank E, Wilson DM, DeSalvo D, Norlander L, Ly T, Buckingham BA, Diner J, Dezube M, Young LA, Goley A, Kirkman MS, Buse JB, Zheng H, Selagamsetty RR, Damiano ER, Russell SJ. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017; 389:369-380. PMID: 28007348.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375:311-22. PMID:27295427

Burant CF, Buse CR, Robinson KA, Buse JB. Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery. Diabetes Care. 2016; 39:852-6. PMID: 27222542.

john-buse